Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydromorphone + butorphanol is a combination of two opioid analgesics used together for pain management, primarily in veterinary and perioperative settings. Hydromorphone is a synthetic full agonist of the μ-opioid receptor (mu), providing potent analgesia suitable for moderate to severe pain. Butorphanol acts as an agonist at the κ-opioid receptor (kappa) and as an antagonist or partial agonist at the μ-opioid receptor, offering milder analgesia with a shorter duration. When combined, butorphanol can reduce some adverse effects associated with pure mu-agonists like hydromorphone (such as dysphoria or excessive sedation), though it may also decrease the intensity of analgesia while extending its duration. This combination has been studied in both human and animal models for multimodal pain control, including post-surgical and procedural settings[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydromorphone + butorphanol.